NovaDel Pharma, Inc.

Pilot study begins using faster acting version of sumatriptan

Published in Law and Health Weekly, June 12th, 2004

NovaDel Pharma, Inc., (NVD) announced that it has commenced a pilot pharmacokinetic feasibility study in humans using its lingual spray technology to achieve a faster acting version of sumatriptan.

Sales of sumatriptan, a migraine remedy marketed as Imitrex in the U.S. by GlaxoSmithKline, are currently more than $1 billion.

The drug's new formulation utilizes NovaDel's patented lingual spray drug-delivery technology to achieve more rapid onset of therapeutic activity. This is considered a desired benefit for patients suffering from a variety of medically treatable conditions, of which migraine headaches are a prime example.

"The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2004-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry